App-Quantinova.ai

LONGER-TERM ANALYSIS OF EFFICACY OF LUSPATERCEPT VERSUS PLACEBO IN PATIENTS WITH TRANSFUSION-DEPENDENT BETA-THALASSEMIA ENROLLED IN THE BELIEVE STUDY

Maria Domenica Cappellini - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Beta-thalassemia

luspatercept

AN ANALYSIS ACROSS ABO BLOOD GROUPS IN PATIENTS WITH COVID-19 INFECTION AND CORRELATION WITH HAEMATOLOGICAL BIOMARKERS, A SINGLE CENTRE STUDY

Hala Shokr - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

N/A

PRELIMINARY ANALYSIS OF THE PHASE II STUDY USING TOLINAPANT (ASTX660) MONOTHERAPY IN 98 PERIPHERAL T-CELL LYMPHOMA AND 51 CUTANEOUS T-CELL LYMPHOMA SUBJECTS WITH RELAPSED REFRACTORY DISEASE.

Jean-Marie Michot - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Peripheral T-cell lymphoma

N/A

FAVEZELIMAB (ANTI–LAG-3) AND PEMBROLIZUMAB CO-BLOCKADE IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA WHO PROGRESSED AFTER ANTI–PD-1 THERAPY: AN OPEN-LABEL PHASE 1/2 STUDY

Alex F. Herrera - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Hodgkin's Lymphoma

Pembrolizumab

T-CELL ACTIVATION AND MYELOMA CELL KILLING CONFIRM THE MODE OF ACTION OF RG6234, A NOVEL GPRC5D T-CELL ENGAGING BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Iryna Dekhtiarenko - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

Uliprisnil acetate

PROJECTED LIFETIME ECONOMIC BURDEN OF TRANSFUSION DEPENDENT BETA-THALASSEMIA IN THE UNITED STATES

Chuka Udeze - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Beta-thalassemia

luspatercept

SYSTEMATIC LITERATURE REVIEW OF THE BURDEN OF ILLNESS AND OUTCOME ANALYSES OF PATIENTS WITH NON-TRANSFUSION DEPENDENT BETA-THALASSEMIA

Yesim Aydinok - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Beta-thalassemia

N/A

THE COMBINATION OF IBRUTINIB PLUS VENETOCLAX RESULTS IN A HIGH RATE OF MRD NEGATIVITY IN PREVIOUSLY UNTREATED CLL: THE RESULTS OF THE PLANNED INTERIM ANALYSIS OF THE PHASE III NCRI FLAIR TRIAL

Peter Hillmen - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Venetoclax

PROACTIVE DASATINIB DOSE REDUCTION IN THE ALLG CML 12 DIRECT STUDY BASED ON TROUGH LEVELS MINIMISE TOXICITY AND PRESERVE EFFICACY

David Yeung - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

dasatinib

LONG-TERM SAFETY RESULTS OF THE BELIEVE STUDY OF LUSPATERCEPT IN ADULTS WITH ΒETA-THALASSEMIA

Vip Viprakasit - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Hypertension

luspatercept

SUBCUTANEOUS EPCORITAMAB IN COMBINATION WITH RITXUIMAB + LENALIDOMIDE IN RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: PHASE 1/2 TRIAL UPDATE

David Belada - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Follicular lymphoma

Lenalidomide

B-CELL MALIGNANCIES TREATED WITH TARGETED DRUGS AND SARS-COV-2 INFECTION. A EUROPEAN HEMATOLOGY ASSOCIATION SURVEY (EPICOVIDEHA)

Maria Stefania Infante - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Non-Hodgkin's Lymphoma

Pembrolizumab

SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN WITH PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): DREAMM-4 STUDY

Attaya Suvannasankha - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

GSK2857916

A FIRST-IN-HUMAN PHASE 1 TRIAL OF NX-1607, A FIRST-IN-CLASS ORAL CBL-B INHIBITOR, IN PATIENTS WITH ADVANCED MALIGNANCIES INCLUDING RICHTER TRANSFORMATION DLBCL

Adam Sharp - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Unspecified Cancer

N/A

REAL-WORLD OUTCOMES WITH FEDRATINIB THERAPY IN PATIENTS WITH PRIMARY MYELOFIBROSIS POST-RUXOLITINIB DISCONTINUATION

Francesco Passamonti - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Myelofibrosis

Ruxolitinib phosphate

USING ARTIFICIAL INTELLIGENCE NEURAL NETWORKS TO OBTAIN AUTOMATED LIVER IRON CONCENTRATION MEASUREMENTS USING MAGNETIC RESONANCE IMAGING – A MULTI-SCANNER VALIDATION STUDY

Tim St Pierre - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Sickle cell anemia

N/A

FRESH FROZEN PLASMA AND THE PRACTICAL MANAGEMENT: A COMPREHENSIVE AUDIT INCLUDING A SYNOPSIS OF CHALLENGES.

Harberth Fernandez Leyva - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

N/A

PROJECTED LIFETIME ECONOMIC BURDEN OF SEVERE SICKLE CELL DISEASE IN THE UNITED STATES

Chuka Udeze - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Sickle cell anemia

N/A

A PHASE 2 STUDY OF IMG-7289 (BOMEDEMSTAT) IN PATIENTS WITH ADVANCED MYELOFIBROSIS

Harinder Gill - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Myelofibrosis

N/A

RARE PHENOTYPE WITH CD33 ABSENT IN ACUTE MYELOID LEUKEMIA MIMICKING MRD POSITIVITY: A CASE REPORT

Leticia O Marani - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute myelocytic leukemia

N/A

Filters

45280 Abstracts